Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ventyx Biosciences Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ventyx Biosciences (VTYX – Research Report) and Nova...

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Novavax (NVAX)

Ventyx Biosciences stock underwent a massive rally after it posted strong results from a clinical trial.


Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTYX	$9.43	-1.87%	1.83M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTYX	$9.43	-1.9%	1.83M
3
4
5
6

VTYX

VTYX

Dividend Overview

Get Ventyx Biosciences Inc. Data in Excel

Get Ventyx Biosciences Inc. Data in Excel